Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: corticosteroids

ACR Advocates for Access to Viscosupplementation for OA

Kelly Tyrrell  |  August 6, 2018

In several U.S. states, Blue Cross/Blue Shield and other insurers have dropped or are considering dropping coverage of hyaluronic acid injection—or viscosupplementation—for patients with knee osteoarthritis. The decision appears to be based on guidelines published by the American Academy of Orthopaedic Surgeons in 2013, which at that time specified that research had not found hyaluronic…

Filed under:Professional Topics Tagged with:American Academy of Orthopaedic SurgeonsCommittee on Rheumatologic Care (CORC)dropping coveragehyaluronic acid injectionknee osteoarthritisviscosupplementation

Treatment Tips for Pulmonary Arterial Hypertension & ILD

Thomas R. Collins  |  July 19, 2018

CHICAGO—About 30 years ago, pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) began to outpace renal crisis as the main causes of death in scleroderma (SSc). But treating these lung complications has proved vexing for clinicians. There is no easy way to predict who will develop PAH. There is no telltale antibody and no…

Filed under:ConditionsSystemic Sclerosis Tagged with:2018 State of the Art Clinical SymposiumcyclophosphamideILDInterstitial Lung Diseasemycophenolate mofetilnintedanibPAHpomalidomide and perfenidonepulmonary arterial hypertensionrituximabSSctocilizumab

Improve Your Recognition & Treatment of Osteoporosis

Jason Liebowitz, MD, FACR  |  July 19, 2018

BALTIMORE—Rheumatologists may not think about osteoporosis on a daily basis, but they should, said Dr. Karl Insogna, the Ensign Professor of Medicine at Yale University School of Medicine and director of the Yale Bone Center in New Haven, Conn., in his recent lecture at the Maryland Society for the Rheumatic Diseases. With approximately 75 million…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:alendronatebisphosphonatesCorticosteroidsdenosumabOsteoporosisraloxifenerisedronateteriparatidezoledronic acid

Phase 3 Trial Results: Blisibimod for Lupus Shows Possible Efficacy

Renée Bacher  |  July 19, 2018

A phase 3 clinical trial in which researchers treated lupus patients with blisibimod, a biologic treatment that inhibits B cell activating factor (BAFF), did not meet its primary endpoint, but did demonstrate evidence of possible efficacy. Researcher Joan T. Merrill, MD, a member of the Oklahoma Medical Research Foundation (OMRF) and OMRF professor of medicine…

Filed under:Biologics/DMARDsConditionsDrug UpdatesSystemic Lupus Erythematosus Tagged with:BAFF inhibitorblisibimod

Epratuzumab May Work for SLE Subgroups

Larry Beresford  |  July 19, 2018

A recent analysis of the monoclonal antibody epratuzumab finds new evidence for its effectiveness in a subset of systemic lupus erythematosus (SLE) patients who have a concurrent diagnosis of Sjögren’s syndrome, a progressive autoimmune disease that affects exocrine glands and is characterized by dry eyes and mouth.1 Sjögren’s can be primary, meaning independent of other…

Filed under:ConditionsSjögren’s DiseaseSystemic Lupus Erythematosus Tagged with:epratuzumabLymphoCideSjogren's

Case Report: Ehlers-Danlos Syndrome Mimicking Vasculitis

Case Report: Ehlers-Danlos Syndrome Mimicking Vasculitis

Catherine (Katie) Donnelly, MB, BCh, BAO, & Surabhi Khanna, MD  |  July 19, 2018

A 43-year-old man with a past medical history of type 2 diabetes mellitus, bilateral inguinal hernia repair as a child and prior cholecystectomy woke from sleep with sudden-onset periumbilical abdominal pain. He was admitted to another hospital, but required transfer to our surgical intensive care unit after a recurrent episode of severe abdominal pain, during…

Filed under:Vasculitis Tagged with:Ehlers-Danlosmimics

Eosinophilia & Hypereosinophilia Diagnosis & Treatment Tips

Thomas R. Collins  |  June 21, 2018

CHICAGO—High eosinophil counts that can’t be explained should concern rheumatologists and spark attempts to identify what’s happening, an expert said at the ACR State-of-the-Art Clinical Symposium in April. “Eosinophil counts over 1,500 (per microliter) should provoke worry,” said Bruce Bochner, MD, professor of medicine in allergy and immunology at Northwestern University Feinberg School of Medicine…

Filed under:Vasculitis Tagged with:Eosinophiliahypereosinophilianeutropenia

Hydroxychloroquine Risk-Benefit Discussion, & a Handy Dosage App

Thomas R. Collins  |  June 21, 2018

CHICAGO—As good an option as hydroxychloroquine (HCQ) is for many patients with rheumatic diseases, such as rheumatoid arthritis and especially lupus, safety must be an important consideration, an expert said at this April’s ACR State-of-the-Art Clinical Symposium. The use of the antimalarial has become a controversial subject, with clinicians trying to balance the drug’s disease-modifying…

Filed under:AppsDrug UpdatesTechnology Tagged with:2018 State of the Art Clinical SymposiumHYDROXYCHLOROQUINEretinal toxicity

Researchers Seek to Predict & Prevent Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc, & Kevin D. Deane, MD, PhD  |  June 21, 2018

Preventing adverse outcomes in individuals who have rheumatic diseases is a daily goal for rheumatologists. For example, rheumatologists prescribe medications and perform screening to prevent erosions in rheumatoid arthritis (RA), renal failure in systemic lupus erythematosus and flares across all diseases. Many of these actions are classified as secondary or tertiary prevention, because individuals have…

Filed under:Rheumatoid Arthritis Tagged with:lifestyleMetricsrisk assessmentRisk Factors

Researchers Compare Nonsurgical Knee OA Treatments

Michele B. Kaufman, PharmD, BCGP  |  May 23, 2018

According to new research, knee OA patients reported greater pain relief from intra-articular corticosteroids, but naproxen was more effective at improving function…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:intra-articular corticosteroidskneeKnee Osteoarthritis (OA)naproxenPainPain Management

  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 44
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences